Bristol-Myers Squibb (BMY) News Today

Toronto Dominion Bank grew its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,256,439 shares of the biopharmaceutical company's stock after

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) issued its quarterly earnings results on Friday. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.40. The firm had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business's revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.75 earnings per share.

Bristol-Myers Squibb (NYSE:BMY) Shares Up 7.9% Following Earnings Beat

Bristol-Myers Squibb (NYSE:BMY) Shares Gap Up After Earnings Beat

Bristol-Myers Squibb (NYSE:BMY) updated its FY 2024 earnings guidance. The company provided EPS guidance of 0.600-0.900 for the period, compared to the consensus estimate of 0.510.

Bristol-Myers Squibb (NYSE:BMY) Trading Up 0.9%

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Research analysts at Zacks Research raised their Q2 2025 EPS estimates for Bristol-Myers Squibb in a report issued on Wednesday, July 24th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $1.79

Bristol-Myers Squibb (NYSE:BMY) Trading 1.4% Higher

UniSuper Management Pty Ltd increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 15.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 215,898 shares of the biopharmaceutical company's stock afte

Bristol-Myers Squibb (NYSE:BMY) Stock Price Down 1.5% Following Analyst Downgrade

Deutsche Bank Aktiengesellschaft decreased their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating on the stock in a report on Tuesday.

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a report released on Monday, July 22nd. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will pos

Bristol-Myers Squibb (NYSE:BMY) Trading Up 0%

Acadian Asset Management LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 76.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 620,324 shares of the biopharmaceutical company's stock after buying an ad

Cantor Fitzgerald reissued a "neutral" rating and issued a $45.00 target price on shares of Bristol-Myers Squibb in a research report on Monday.

TIAA Trust National Association increased its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 245.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 419,445 shares of the biopharma

Mizuho Markets Americas LLC acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 220,000 shares of the biopharmaceutical comp

Blair William & Co. IL decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 21.8% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 675,610 shares of the biopharmaceutical company's stock after selling 188,760 shares during the period